USPTO serial 76463480
ALCEDO
Reviewed by CopyMark Law Group
Reg. 3596897Status 710
- Filing date
- Status date
- Registration date
- Mar 31, 2009
- Examiner
- CASE, LEIGH CAROLINE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ALCEDO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
28359 Brenmcn, DE
28359 Brenmcn, DE
28359 Brenmcn, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew J. Smith
Brian B. Diekhoff Polsinelli Shughart PC100 South Fourth StreetSuite 1000St. Louis, MO 63102Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, agriculture, horticulture and forestry, namely, proteins, peptides, nucleic acids and polynucleotides; proteins and recombinant proteins for scientific research use, antibodies for scientific research use; DNA probes for scientific research use; oligonucleotides for scientific research use; antibodies for scientific research use; DNA probes for scientific research use; oligonucleotides for scientific research use; antisense constructs for scientific research use; arrays of nucleic acids or proteins on a carrier material for scientific research use; single nucleotide polymorphism kits, also called SNP kits comprising at least one oligonucleotide or a polynucleotide for scientific research use; expression profiling kits comprised of an antibody, a protein, a peptide, a nucleic acid, a polynucleotide or a probe for scientific research use, in particular by use of PCR, immunohistochemistry or arrays; kits comprised of an antibody, a protein, a peptide, a nucleic acid, a polynucleotide or a probe for indication of specific therapy approaches for scientific research use, in particular FISH, arrays, PCR and immunohistochemistry; kits comprised of an antibody, a protein, a peptide, a nucleic acid, a polynucleotide or a probe for detection of predisposition for particular diseases for research purposes, in particular by using PCR, MALDITOF and oligo hybridization; cartilage cells for scientific research use, in particular implantable cartilage cells; fat cells for scientific research use, in particular implantable fat cells; adult and fetal stem cells for scientific research use; kits comprised of an antibody, a protein, a peptide, a nucleic acid, a polynucleotide or a probe for purification and/or separation of nucleic acids for scientific research use; kits for purification or separation of nucleic acids for scientific research use | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical and veterinary products, namely, slimming, appetite suppressants, pharmaceuticals for acidosis therapeutics, analeptic antihypoxaemics; analgesics and antirheumatic drugs, pharmaceuticals functioning antihelminitics, antiallergics, antianemia drugs, antiarrhythmics, antibiotics and antiinfectives, antidementics, nootropics, antidiabetics, antidotes for the treatment of poisoning, antiemetics and antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolyrics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, pharmaceuticals functioning as antiparasitics, antiphlogistics, antitussives, expectorants for use in atherosclerosis, belneotherapeutics and pharmaceuticals for thermal therapy, pharmaceuticals functioning as beta receptor blocking agents, pharmaceuticals for calcium channel blocking and inhibiting of the renin angiotensin-system, pharmaceuticals functioning as broncholytics, antiasthmetics, cholagoguegics and for use in biliary tract therapeutics; pharmaceuticals functioning as cholinergics, corticoids, dermatics; all purpose disinfectants and antiseptics; pharmaceuticals functioning as dietetic agents and in alimentary therapeutics; pharmaceutical preparations functioning as diuretics, as agents for favoring blood flow, as withdrawal agents, as fibrinolytics, to treat gout, the flu and catarrhal fever; pharmaceuticals for the treatment of gynecological illnesses, namely, menstrual cramps, hemorrhoids, hepatitis; pharmaceuticals functioning as hypnotics and sedatives; pharmaceuticals to treat cardiac ailments; pharmaceuticals for use in caries and parodontosis; dental preparations, namely, dental abrasives; laxatives, pharmaceuticals functioning as antilipaemics, local anesthetics, neural therapeutics, gastro-intestinal preparations, pharmaceuticals to treat migraines; pharmaceutical preparations for use in mouth and pharyngeal therapeutics; pharmaceuticals for use as muscle relaxants; pharmaceuticals for the treatment of addiction to narcotics; pharmaceuticals for use in neuropathology; ophthalmic pharmaceuticals for treating blindness, conjunctivitis, cataract, glaucoma, retinal detachment, stye chalazion, dacryoadenitis, corneal clouding, keratitis, gasserian ganglionitis, vitreous opacity, amaurosis, retinopathy, central retinal artery occlusion, retinoblastoma, melanoma, optic neuritis, optic nerve atrophy; pharmaceuticals for use in osteoporosis and calcium metabolism modification; pharmaceuticals for the treatment of Parkinson's Disease and disturbances of the extrapyramidal system; pharmaceuticals for psychotropic, rhinologic and sinostic purposes; pharmaceuticals functioning as roborants and tonics; pharmaceuticals for use in thyroidal therapeutics; pharmaceuticals functioning as spasmolytics and inhibitors of thrombocyte aggregation; pharmaceuticals for the treatment of tuberculosis; pharmaceuticals functioning as alternants, urologics and venous agents; vitamins; pharmaceuticals for use as cytostatics and antineoplastic agents; veterinary preparations for the use in the treatment of distemper, macular degeneration, cancer, infertility, arthritis, dermatitis, infections, sepsis, cardiovascular diseases, artheriosclerosis, diabetes and obesity in pets, livestock, wild animals, breeding animals and zoo animals; dietetic substances adapted for medical use, namely, food for elderly people who require medically restricted diets; medical plasters; materials for dressings, namely, wound, burn and surgical dressings; all-purpose disinfectants; preparations for destroying vermin; fungicides for domestic or agricultural use; herbicides for domestic or agricultural use; wound medicines; wound ointment; wound spray; wound tincture; wound fleece; fleece against restenosis, in particular after vascular surgery; medicaments against artheriosclerosis; medicaments against restenosis; medicaments for tissue regeneration and tissue replacement; medicaments for cartilage regeneration; pharmaceutical and veterinary preparations for diabetes treatment; pharmaceutical and veterinary preparations for diabetes prophylaxis; implantable cartilage cells; implantable fat cells; adult and fetal stem cells for medical diagnostic or therapeutic use; medicaments against obesity; pharmaceutical and veterinary preparations for pets, livestock, wild animals, breeding animals and zoo animals against tumors; gene therapeutic preparations against tumors; pharmaceutical and veterinary preparations for use in pets, livestock, wild animals, breeding animals and zoo animals against endometriosis; pharmaceutical and veterinary preparations pets, livestock, wild animals, breeding animals and zoo animals for tissue modeling for medical diagnostic or therapeutic use; recombinant proteins for medical diagnostic or therapeutic use; antibodies for medical diagnostic or therapeutic use; DNA probes for medical diagnostic use; target oligonucleotides for medical diagnostic or therapeutic use; antisense constructs; small molecules for medical diagnostic or therapeutic use; anticalines for medical diagnostic or therapeutic use; aptamers for medical diagnostic or therapeutic use; spiegelmers for medical diagnostic or therapeutic use; ribozymes for medical diagnostic or therapeutic use; RNAi for medical diagnostic or therapeutic use; specific oligonucleotides for medical diagnostic or therapeutic use; DNA probes for medical diagnostic or therapeutic use; single nucleotide polymorphism kits known as SNP kits comprised of proteins, peptides, nucleic acids or oligonucleotides for medical diagnostic use; expression profiling kits comprised of proteins, peptides, nucleic acids or oligonucleotides for medical diagnostic use, in particular by use of PCR immunohistochemistry or arrays; kits comprised of proteins, peptides, nucleic acids or oligonucleotides for medical diagnostic use for indication of specific therapy approaches, in particular FISH arrays, PCR and immunohistrochemistry; kits comprised of proteins, peptides, nucleic acids, or oligonucleotides for medical diagnostic use for detection of predisposition for particular diseases, in particular by using PCR, MALDITOF, and oligo hybridization; kits comprised of proteins, peptides, nucleic acids or oligonucleotides for medical diagnostic use for purification and/or separation of nucleic acids | SECTION 8 - CANCELLED | — |
| 009 | Scientific control apparatus and instruments, namely, microscopes, ELISA readers, scanners, fluorescence readers, phosphorirnagers; apparatus for recording, transmission or reproduction of sound or images, namely, cameras, ELISA readers, scanners, fluorescence readers, phosphorimagers; prerecorded magnetic data carriers featuring biological data of a sample or group of samples; data processing equipment, namely, ELISA readers, scanners, fluorescence readers, phosphorimagers; computers; stored computer programs for use in database management, for use as a spreadsheet, for word processing or analysis of biological data of a sample or group of samples; stored computer software for use in database management, for use as a spreadsheet, for word processing or analysis of biological data of a sample or group of samples; programs, in particular computer programs for analysis of patterns of surfaces, in particular of patterns of arrays of nucleic acids or proteins on carrier materials; automated expression profiles, namely, software for analysis of expression profiles | SECTION 8 - CANCELLED | — |
| 010 | Surgical, medical, dental and veterinary instruments and apparatus, namely, medical tubing, syringes, surgical implants and dental implants for the administration of fluid, gels, solids and solidifying systems; artificial limbs; orthopedic articles, namely, bone implants, cartilage implants and neck braces | SECTION 8 - CANCELLED | — |
| 040 | Treatment of materials, namely, custom construction of therapeutically useful substances into liposomes; custom construction of therapeutically useful substances in carrier substances; custom manufacture of recombinant proteins for third parties; custom manufacture of antibodies for third parties; custom manufacture of gene and tissue arrays for third parties; custom manufacture of specific oligonucleotides for third parties; custom cultivation of cells, in particular of animal and/or human cells for third parties; custom manufacture of functional nucleic acids, in particular ribozymes, aptamers, spiegelmers, RNAi and antisense oligonucleotides for third parties | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services, namely, designing laboratory protocols, manufacturing protocols and clinical trial protocols; industrial analysis and research services, namely, in the field of biology, biotechnology, biochemistry, genetics, chemistry, medicine, veterinary medicine and pharmacy; design and development of computer hardware and software; scientific research in the nature of construction of viral vectors, namely, for medication; expression profile analyses, namely, by PCR, immunohistochemistry or array hybridization; mapping of genes, in particular of chromosomes and gene libraries; hybridizations of gene libraries; performing single nucleotide polymorphism (SNP) analysis; performing fluorescent in situ hybridizations (FISH) analysis, arrays, PCR analysis, immunohistochemistry analysis; scientific research in the nature of detection of predisposition for developing particular diseases, in particular by using PCR or oligo hybridization; designing computer programs for others for scientific and technological services and research; designing computer programs, namely, computer programs for industrial analysis and research activities; providing a data base for scientific use on the subject of genetics, biology, pharmacy, biotechnology, medicine, veterinary medicine, biochemistry and chemistry by collecting, storing and offering of software, data, images, audio and video; providing non-downloadable software on the subject of chemical, pharmaceutical, biotechnological, biological, medical and veterinary research services, namely, legal or consulting services relating to exploitation concepts for biotechnological inventions and biotechnological know-how; scientific research in the nature of design and realization of animal experiments and design and realization of therapy studies, and analysis for specific therapy approaches | SECTION 8 - CANCELLED | — |
| 044 | Medical and veterinary services; health care for humans and animals; beauty salons; grooming salons for animals; plastic tissue regeneration; cosmetic tissue modeling and tissue regeneration | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alcedo Biotech GmbH
- Other trademarks owned by Alcedo Biotech GmbH
- Other trademarks owned by Alcedo Biotech GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ALCEDO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 6, 2015 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Dec 22, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 3, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 31, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 13, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 24, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 9, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 2, 2008 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Dec 2, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 2, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 2, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 17, 2008 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 3, 2008 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Oct 22, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 21, 2008 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Oct 21, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 21, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 21, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 18, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 18, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 15, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 22, 2008 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 22, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2008 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 24, 2008 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Mar 6, 2008 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Nov 20, 2007 | ALIE | ASSIGNED TO LIE | — |
| Oct 18, 2007 | PAPER RECEIVED | — | |
| Mar 25, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Feb 28, 2005 | UNPR | UNRESPONSIVE/DUPLICATE PAPER RECEIVED | — |
| Feb 28, 2005 | PAPER RECEIVED | — | |
| Feb 22, 2005 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 4, 2005 | ALIE | ASSIGNED TO LIE | — |
| Jan 28, 2005 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 27, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Jan 11, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 11, 2005 | PAPER RECEIVED | — | |
| Jul 16, 2004 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 18, 2004 | PAPER RECEIVED | — | |
| May 3, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 3, 2004 | PAPER RECEIVED | — | |
| Oct 23, 2003 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Sep 10, 2003 | CFIT | CASE FILE IN TICRS | — |
| Aug 26, 2003 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Aug 26, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 26, 2003 | PAPER RECEIVED | — | |
| Feb 26, 2003 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 21, 2003 | DOCK | ASSIGNED TO EXAMINER | — |